Press releases
2020
30 December, 2020
Change in the number of shares and votes in Egetis Therapeutics
22 December, 2020
Nomination Committee appointed for the 2021 Annual General Meeting in Egetis Therapeutics
17 December, 2020
PledPharma changes its name to Egetis Therapeutics with focus on late stage orphan drug development
15 December, 2020
Results from the prematurely closed PledOx POLAR program
11 December, 2020
Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 11 December 2020
7 December, 2020
First patient dosed in Phase IIb/III study with Emcitate®
30 November, 2020
Change in the number of shares and votes in PledPharma
25 November, 2020
PledPharma raises SEK 250 million in oversubscribed rights issue and utilized overallotment option
23 November, 2020
Clarification regarding ownership changes in PledPharma
18 November, 2020
FDA grants Rare Pediatric Disease designation to Emcitate®
12 November, 2020
PledPharma publishes a supplement to the prospectus
11 November, 2020
Interim Report January 1-September 30, 2020
10 November, 2020
NOTICE TO ATTEND EXTRAORDINARY GENERAL MEETING IN PLEDPHARMA AB
6 November, 2020
Henrik Krook appointed VP Commercial Operations at PledPharma
5 November, 2020
PledPharma publishes prospectus and updated financial information in connection with fully guaranteed rights issue and the admission to trading of shares
3 November, 2020
PledPharma completes the acquisition of Rare Thyroid Therapeutics
28 October, 2020
Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 28 October 2020
14 October, 2020
Design of pivotal Phase IIb/III study for Aladote® finalized after completed interactions with FDA, EMA and MHRA
5 October, 2020
Notice of Extraordinary general meeting in PledPharma AB
5 October, 2020
PledPharma to acquire Rare Thyroid Therapeutics, creating a new focused orphan drug development company
20 August, 2020
Half-Year report January-June 2020
Calendar and upcoming reports
April 15, 2024
Annual Report 2023
May 3, 2024
Interim Report Q1 2024 (7:00am CEST)
